J. Andrew Livingston, M.D., M.S.
Department of Sarcoma Medical Oncology, Division of Cancer Medicine
About Dr. Livingston
Dr. Livingston is a clinician and researcher in Sarcoma Medical Oncology and holds a joint appointment in Pediatric Oncology. After completing medical school at the University of Texas Medical Branch at Galveston, he went on to residency training at Duke University where he completed a combined residency in internal medicine and pediatrics. Dr. Livingston completed his fellowship training here at MD Anderson where he served as the Chief Fellow for Hematology/Oncology Fellowship Program. Dr. Livingston has a particular interest in the care of teens and young adults with cancer and is Co-director of the MD Anderson Adolescent and Young Adult (AYA) oncology program. His clinical and translational research is focused on developing new treatment strategies for patients with osteosarcoma and other bone sarcomas.
Present Title & Affiliation
Primary Appointment
Associate Professor, Department of Sarcoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Associate Professor, Department of Pediatrics Patient Care, Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2017 | University of Texas Graduate School of Biomedical Sciences, Houston, TX, USA, MS, Biomedical sciences, Clinical/Translational Research |
| 2009 | University of Texas Medical Branch, Galveston, TX, USA, MD, Medicine |
| 2005 | University of Colorado, Boulder, CO, USA, BA, Biochemistry |
Postgraduate Training
| 2015-2016 | Chief Fellow, Hematology and Medical Oncology Fellowship Program, University of Texas MD Anderson Cancer Center, Houston, TX |
| 2013-2016 | Clinical Fellowship, Hematology and Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX |
| 2009-2013 | Clinical Residency, Combined program in Internal Medicine and Pediatrics, Duke University Medical Center, Durham, NC |
Board Certifications
| 2016 | American Board of Internal Medicine-Hematology |
| 2016 | American Board of Internal Medicine-Medical Oncology |
| 2014 | American Board of Internal Medicine |
| 2013 | American Board of Pediatrics |
Experience & Service
Administrative Appointments/Responsibilities
Co-Director, Department of Adolescent and Young Adult Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2016 - Present
Institutional Committee Activities
Member, Clinical Research Advisory Committee, 2018 - 2022
Member, MD Anderson Young Adult Advisory Council, 2016 - Present
Honors & Awards
| 2020 | OutSmarting Osteosarcoma Award, MIB Agents |
| 2016 | ASCO/CCF Young Investigator Award |
| 2016 | Paul Calabresi Scholar in Clinical Oncology Research, National Cancer Institute |
| 2015 | Connie and Jim Walter Endowed Fellowship in Sarcoma Research, The University of Texas MD Anderson Cancer Center |
| 2008 | Gold Humanism Honor Society |
| 2008 | Alpha Omega Alpha Honor Society |
| 2005 | Phi Beta Kappa, University of Colorado |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Wu CC, Wang YA, Livingston JA, Zhang J, Futreal PA. Prediction of biomarkers and therapeutic combinations for anti-PD-1 immunotherapy using the global gene network association. Nat Commun 13(1):42, 2022. e-Pub 2022. PMID: 35013211.
- Mull BB, Livingston JA, Patel N, Bui T, Hunt KK, Keyomarsi K. Specific, reversible G1 arrest by UCN-01 in vivo provides cytostatic protection of normal cells against cytotoxic chemotherapy in breast cancer. Br J Cancer 122(6):812-822, 2020. e-Pub 2020. PMID: 31942030.
- Wu CC, Beird HC, Andrew Livingston J, Advani S, Mitra A, Cao S, Reuben A, Ingram D, Wang WL, Ju Z, Hong Leung C, Lin H, Zheng Y, Roszik J, Wang W, Patel S, Benjamin RS, Somaiah N, Conley AP, Mills GB, Hwu P, Gorlick R, Lazar A, Daw NC, Lewis V, Futreal PA. Immuno-genomic landscape of osteosarcoma. Nat Commun 11(1):1008, 2020. e-Pub 2020. PMID: 32081846.
- Bishop AJ, Bird JE, Conley AP, Roland CL, Moon BS, Satcher RL, Livingston JA, Patel S, Wang WL, Lazar AJ, Lewis VO, Lin PP, Guadagnolo BA. Extraskeletal Myxoid Chondrosarcomas: Combined Modality Therapy with both Radiation and Surgery Improves Local Control. Am J Clin Oncol 42(10):744-748, 2019. PMID: 31436747.
- Roszik J, Khan A, Conley AP, Livingston JA, Groisberg R, Ravi V, Carmagnani Pestana R, Sen S, Subbiah V. Unique Aberrations in Intimal Sarcoma Identified by Next-Generation Sequencing as Potential Therapy Targets. Cancers (Basel) 11(9), 2019. e-Pub 2019. PMID: 31480474.
- Zhao Q, Hu J, Mitra A, Cutrera J, Zhang W, Zhang Z, Yan J, Xia X, Mahadeo KM, Livingston JA, Gorlick R, Li S. Tumor-targeted IL-12 combined with tumor resection yields a survival-favorable immune profile. J Immunother Cancer 7(1):154, 2019. e-Pub 2019. PMID: 31208461.
- Conley AP, Wang WL, Livingston JA, Ravi V, Tsai JW, Ali A, Ingram DR, Lowery CD, Roland CL, Somaiah N, Hwu P, Yee C, Subbiah V, Futreal A, Lazar AJ, Patel S, Roszik J. MAGE-A3 is a Clinically Relevant Target in Undifferentiated Pleomorphic Sarcoma/Myxofibrosarcoma. Cancers (Basel) 11(5), 2019. e-Pub 2019. PMID: 31096717.
- Bishop AJ, Livingston JA, Araujo DM, Moon BS, Patel S, Wang WL, Lazar AJ, Roland CL, Guadagnolo BA. Extraskeletal Osteosarcomas: A Case Made for Combined Modality Local Therapy With Radiation and Surgery. Am J Clin Oncol 42(3):238-242, 2019. e-Pub 2019. PMID: 30614820.
- Gilchrist SC, Roth M, Livingston JA, Hildebrandt MAT, Kleinerman ES, Banchs J. Short-Term Changes in Cardiac Function in Osteosarcoma Patients Receiving Anthracyclines. J Adolesc Young Adult Oncol. e-Pub 2019. PMID: 30794081.
- Avila JC, Livingston JA, Rodriguez AM, Kirchhoff AC, Kuo YF, Kaul S. Disparities in Adolescent and Young Adult Sarcoma Survival: Analyses of the Texas Cancer Registry and the National SEER Data. J Adolesc Young Adult Oncol 7(6):681-687, 2018. e-Pub 2018. PMID: 30096005.
- Kaul S, Russell H, Livingston JA, Kirchhoff AC, Jupiter D. Emergency Department Visits by Adolescent and Young Adult Cancer Patients Compared with Pediatric Cancer Patients in the United States. J Adolesc Young Adult Oncol 7(5):553-564, 2018. e-Pub 2018. PMID: 29924663.
- Livingston JA, Wang WL, Tsai JW, Lazar AJ, Leung CH, Lin H, Advani S, Daw N, Santiago-O'Farrill J, Hollomon M, Gordon NB, Kleinerman ES. Analysis of HSP27 and the autophagy marker LC3B+ puncta following preoperative chemotherapy identifies high-risk osteosarcoma patients. Mol Cancer Ther 17(6):1315-1323, 2018. e-Pub 2018. PMID: 29592877.
- Wagner MJ, Gopalakrishnan V, Ravi V, Livingston JA, Conley AP, Araujo D, Somaiah N, Zarzour MA, Ratan R, Wang WL, Patel SR, Lazar A, Ludwig JA, Benjamin RS. Vincristine, Ifosfamide, and Doxorubicin for Initial Treatment of Ewing Sarcoma in Adults. Oncologist 22(10):1271-1277, 2017. e-Pub 2017. PMID: 28710342.
- Livingston JA, Bugano D, Barbo A, Lin H, Madewell JE, Wang WL, Lazar AJ, Tseng WW, Roland CL, Feig BW, Pollock R, Conley AP, Benjamin RS, Patel S, Somaiah N. Role of chemotherapy in dedifferentiated liposarcoma of the retroperitoneum: defining the benefit and challenges of the standard. Sci Rep 7(1):11836, 2017. e-Pub 2017. PMID: 28928422.
- Santiago-O'Farrill JM, Kleinerman ES, Hollomon MG, Livingston A, Wang WL, Tsai JW, Gordon NB. Phosphorylated heat shock protein 27 as a potential biomarker to predict the role of chemotherapy-induced autophagy in osteosarcoma response to therapy. Oncotarget 9(2):1602-1616, 2017. e-Pub 2017. PMID: 29416717.
- McManus M, Kleinerman E, Yang Y, Livingston JA, Mortus J, Rivera R, Zweidler-McKay P, Schadler K. Hes4: A potential prognostic biomarker for newly diagnosed patients with high-grade osteosarcoma. Pediatr Blood Cancer 64(5), 2017. e-Pub 2016. PMID: 27786411.
Invited Articles
- Beird HC, Bielack SS, Flanagan AM, Gill J, Heymann D, Janeway KA, Livingston JA, Roberts RD, Strauss SJ, Gorlick R. Osteosarcoma. Nat Rev Dis Primers 8(1):77, 2022. e-Pub 2022. PMID: 36481668.
- El Beaino M, Roszik J, Livingston JA, Wang WL, Lazar AJ, Amini B, Subbiah V, Lewis V, Conley AP. Mesenchymal chondrosarcoma: A review with emphasis on its fusion-driven biology. Curr Oncol Rep 20(5):37, 2018. e-Pub 2018. PMID: 29582189.
- Roszik J, Wang WL, Livingston JA, Roland CL, Ravi V, Yee C, Hwu P, Futreal A, Lazar AJ, Patel SR, Conley AP. Overexpressed PRAME is a potential immunotherapy target in sarcoma subtypes. Clin Sarcoma Res 7:11, 2017. e-Pub 2017. PMID: 28630682.
Editorials
- Livingston JA. Improving Outcomes for Adolescents and Young Adults With Sarcoma: A Focus on Cancer Care Delivery. J Oncol Pract 15(5):253-254, 2019. PMID: 31075216.
Abstracts
- Wang WL, Lazar A, Wu CC, Beird H, Ingram D, Khan S, Wani K, Daw N, Futreal A, Livingston JA. DNA Damage Response Deficiency in Osteosarcoma. CTOS Annual Meeting, 2019.
- McCall D, Roszik J, Cuglievan B, Ludwig J, Zarzour M, Gill J, Livingston JA, Subbiah V. EWS-Fusion Partners in Sarcoma as Revealed by "Real World" Genomic Sequencing: Clinical Implications. CTOS Annual Meeting, 2019.
- D'Angelo S, Conley A, Kelly C, Dickson M, Gounder M, Chi P, Livingston JA, Patel S, Adamson T, Kiesler H, Hwang S, Tap W. Pilot study of NKTR214 and nivolumab in patients with sarcomas. ASCO Annual Meeting, 2019.
- Amaria R, Bernatchez C, Forget MA, Haymaker C, Conley A, Livingston JA, Varadachary G, Java M, Mitra A, Tzeng C, Hinchiff E, Bayer V, Hilton T, Celestiino J, Rangel K, Yuan Y, Lu K, Hwu P, Jazaeri A. Adoptive transfer of tumor-infiltrating lymphocytes in patients with sarcomas, ovarian, and pancreatic cancers. ASCO Annual Meeting, 2019.
- Livingston JA, Posey K, Wang WL et al. Chemotherapy in the treatment of undifferentiated high grade pleomorphic sarcoma of bone. CTOS Annual Meeting, 2018.
- Livingston JA, Beird HC, Wu C, Cao, Advani, Ingram, Wang WL, Lazar AJ, Leung, Lin, Reuben, Roszik, Wang W, Patel S, Benjamin R, Gorlick R, Lewis V, Futreal PA, Daw N. Parallel genomic and immune profiling of relapsed and metastatic osteosarcoma to reveal bases of low immunogenicity. ASCO Annual Meeting, 2018.
- Wu C, Beird HC, Livingston JA, Cao, Advani, Ingram, Wang WL, Lazar AJ, Leung, Lin, Reuben, Roszik, Wang W, Patel S, Benjamin R, Gorlick R, Lewis V, Daw N, Futreal PA. Genome and transcriptome profiling of relapsed and metastatic osteosarcoma. ASCO Annual Meeting, 2018.
- Livingston JA, Posey K, Subbiah VS, Daw N, Somaiah N, Ravi V, Patel S, Benjamin RS, Wang WL, Lazar AJ, Broaddus R, Meric-Bernstam F, Shaw K, Roszik J, Conley AP. Analysis of osteosarcoma subtypes by clinical genomic testing to identify clinically actionable alterations. ASCO Annual Meeting, 2017.
- Avila JC, Livingston JA, Rodriguez A, Kirchoff AC, Kue TF, Kaul S. Disparities in Survival Among Adolescent and Young Adult Patients with Sarcomas in Texas. AACR Annual Meeting 2017, 2017.
- Roszik J, Conley AP, Livingston JA, Ravi V, Lazar A. Next-generation sequencing identifies immunotherapy targets in soft tissue sarcoma. Connective Tissue Oncology Society Annual Meeting, 2017.
- Conley AP, Livingston JA et al. Assessment of next-generation sequencing (NGS) for patients with chondrosarcoma. CTOS Annual Meeting, 2017.
- Ratan R, Livingston JA et al. CIC rearranged sarcomas. CTOS Annual Meeting, 2017.
- Subbiah V, Conley A, Livingston JA, Lazar A, Meric-Bernstam F, Futreal A, Roszik J. Picking Antibody-drug conjugate targets for drug development for sarcoma: Diving deeper into TCGA. CTOS Annual Meeting, 2017.
Book Chapters
- Wu CC, Livingston JA. Genomics and the Immune Landscape of Osteosarcoma. In: Adv Exp Med Biol. Springer, 21-36, 2020.
Grant & Contract Support
| Title: | Conquer Cancer Foundation/Quad W Young Investigator Award in Memory of Willie Tichenor |
| Funding Source: | American Society of Clinical Oncology (ASCO) |
| Role: | Principal Investigator |
| Title: | Paul Calabresi Clinical Oncology Research Career Development Program |
| Funding Source: | NIH/NCI |
| Role: | Investigator |
| Title: | A phase 2 trial of durvalumab and oleclumab in AYAs with metastatic osteosarcoma |
| Funding Source: | Osteosarcoma Institute |
| Role: | Principal Investigator |
| Title: | OutSmarting Osteosarcoma |
| Funding Source: | MIB Agents |
| Role: | Principal Investigator |
| Title: | Doxorubicin-Induced Cardiotoxicity: Defining Blood and Echocardiogram Biomarkers in a Mouse Model and AYA Sarcoma Patients for Evaluating Exercise Interventions |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-Investigator |
| Title: | MD Anderson Sarcoma SPORE |
| Funding Source: | NIH/NCI |
| Role: | Project 2 Leader |
| Title: | Characterization of DNA-Damage Response and Repair Pathways in Sarcoma |
| Funding Source: | Repare Therapeutics |
| Role: | Principal Investigator |
Patient Reviews
CV information above last modified December 04, 2024